The US Food and Drug Administration has approved the first drug to help image tau neurofibrillary tangles in the brain, a primary marker of Alzheimer’s disease. The radioactive diagnostic agent, Tauvid (flortaucipir F18), is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of the neurofibrillary tangles.

The European Medicines Agency has signed a contract with Utrecht University in the Netherlands to gather real-world evidence on the safety and effectiveness of any new COVID-19 vaccines that are launched on the market. According to the World Health Organization, 10 candidate vaccines were in clinical development as of 30 May. Most of these molecules are in early human studies, but with pressure mounting to arrest the coronavirus pandemic, the development of the candidate vaccines is accelerating.